Archive
Latest
Every article, newest first. 56 stories, each built from a primary source.
- Science
Ukraine's Starlink 100 mph Cap: Who Holds the Off Switch
Kyiv blames SpaceX, Musk points to Washington, and Eutelsat jumped about 23% in Paris. The fight over one speed limit exposes who really controls the satellites.
- Economy
U.S. Social Security COLA: Why 2027's Raise Is 3.6%, Not 3.9%
The legal formula averages July to September, so September's gasoline spike counts for only a third, and the Medicare premium that trims the raise is not set yet.
- Body & Longevity
AUF1 Gene Therapy Limited Muscle Loss After Injury in Mice
Mice kept near normal strength after a severe muscle injury when given extra AUF1, by virus or by mRNA. Two authors cofounded the company developing it, and no human has received it.
- Body & Longevity
An Oral Pill for Angioedema Attacks: Relief in 1.3 Hours
A crossover trial in a rare disease, funded by the drugmaker: each patient treated one attack with the pill and one with placebo. The result is large and the analysis smaller than the enrollment.
- Body & Longevity
A Parkinson's Pill That Skips Dopamine Cut Off Time by 37 Minutes
A new mechanism, a positive primary endpoint and a modest effect size. Everything here comes from a company release and a congress talk, not a peer reviewed paper.
- Evidence Guides
A Long COVID Trial Was Retracted. Half of It Still Stands
A dose cut and an early stop were applied in the trial but left out of the analysis. The fix downgraded one drug and left the other untouched.
- AI at Work
Reading Iambic's S-1: An AI Drug IPO, Risk Factors First
One drug in early clinical testing, a $245 million accumulated deficit, and a platform the company itself calls unproven. The prospectus is more candid than the headlines.
- Body & Longevity
Seven FDA Decisions Due by Christmas, and the Trials Behind Them
Every date below comes from the company itself. CagriSema has no published goal date, only a quarter. One file arrives after an advisory committee voted 9 to 3 against.
- AI at Work
Anthropic Moves Into Biology: What Is Announced vs Shown
Four launches in three months. One produced a preprint about an enzyme system whose function is still unknown. The rest are access rules, pilots and promises.
- Body & Longevity
Where Your Arm Rests Can Add 6 Points to a Blood Pressure Reading
Lap: +3.9 mmHg systolic. Arm at your side: +6.5. A randomized trial measured the couch error, and the fix is a table and five quiet minutes.
- Body & Longevity
Semaglutide's Heart Benefit Is Not Just About Weight Loss
Known risk factors explain at most about half of the 20% drop in heart events, and the frailest patients still benefit. Widening eligibility to a BMI of 25 is a different question.
- Body & Longevity
Orforglipron Worked Across Menopause Stages, With One Asterisk
Women lost 12.8% to 14.4% of their weight on the top dose without diabetes. The diabetes trial tells a shakier story, built partly on a subgroup of 10 women.
- Body & Longevity
One Insulin Shot a Week: What the Efsitora Approval Covers
Efsitora matched daily insulin on HbA1c in four trials and trades 365 injections for 52. In type 1 diabetes, severe lows were three times as common, which is why the label stops at type 2.
- Body & Longevity
Patch Pumps, Implanted Sensors and a Year of Omnipod 5 Data
Omnipod 5 users kept 4.3 extra hours a day in range for a year. Beta Bionics' Mint is cleared but launches in 2027, and its new algorithm still awaits the FDA.
- Body & Longevity
Eight Hours or Nine? What Eating Window Trials Actually Show
Shorter windows meant a few more pounds lost over months. Against a dietitian, a 9 hour window did no better on blood sugar, and both groups lost the same weight.
- Body & Longevity
Half of Young Adults in RESET Put Type 2 Diabetes in Remission
27 of 50 reached remission in 24 weeks, against 2 of 46 on usual care, and they lost fat without losing lean mass. A 1.6 million patient study shows the stakes of waiting.
- AI at Work
AI Worms on $55 TV Boxes: What Anthropic Actually Showed
One open model copied itself across a test network with a deliberately easy exploit. The claim that small models will match it by year end rests on a trend line.
- AI at Work
An AI Epilepsy Monitor Learned From Patients. False Alarms Fell 77.8% in a Replay
Patient feedback retrained a seizure detector and cut false alarms by a median 77.8% in 13 inpatients. The retraining was tested in a replay, not live.
- Science
Artemis II Saw Impact Flashes and a Moon That Isn't Gray
Three astronauts spotted five pinprick impact flashes during an eclipse, and described a Moon tinted brown, green and blue. A preliminary report.
- AI at Work
Why Claude Hides Its Reasoning: The Distillation Arms Race
A copy trained on Claude's full reasoning scored 80.4% on a coding test, 71.8% on summaries. Anthropic says theft is down 90 to 99%, by its own count.
- Body & Longevity
Can Brain Training Delay Dementia? A 20 Year Trial, Read Closely
One arm of a 1990s trial saw fewer dementia diagnoses over 20 years. Five others did not, and the statistics are being argued in public.
- Science
K2-18b's Life Signal: What Webb Saw and What It Didn't
A three sigma hint of dimethyl sulfide made headlines. Most independent reanalyses of the same data don't find it, and the gas exists on a comet too.
- AI at Work
AI Is Breaking the First Rung of the Career Ladder
Employment of 22 to 25 year olds in the most AI exposed jobs sits 19% below trend. The cause is fewer hires, not more layoffs.
- Economy
Nvidia's $530 Billion Isn't Hidden Debt. Read the 10-Q
Three tables add up to $530 billion. Most of it is a shopping list. The part worth watching is a $105 billion guarantee for one OpenAI site.
- Science
Gooier Marine Snow Locks Away More Ocean Carbon
Bacteria struggle to break into the gooiest marine snow, so it sinks deeper. The headline sixfold carbon figure comes from simulations, not the sea.
- Science
Is Antimatter Escaping the Milky Way? Read the Sigma First
Faint 511 keV hotspots match gas clouds beyond the galaxy. If real, the Milky Way makes even more antimatter than anyone can explain. If.
- Economy
The Economics Nobel Behind Every Fed Rate Decision
Hall showed why spending changes are unpredictable. Woodford built the model central banks run. Together they explain why the Fed talks so much.
- Science
Google's 890 MW Nuclear Deal Builds No New Reactor
890 MW of new power from upgrades at 11 existing units, first by 2028. The other 2,700 MW in the headline was already on the grid.
- Science
One Gentoo Penguin or Four? Genomes Split the Species
Genomes from ten colonies split the gentoo into four lineages. Three may lose most of their habitat by 2050, masked by one that is thriving.
- AI at Work
The Free AI Tutor That Lowered Grades
A randomized trial of 2,379 students. The tutor was free, patient, and built on GPT-4o. Grades fell anyway.
- Body & Longevity
Strokes Before 55 Nearly Doubled. Heart Attacks Went the Other Way
Cincinnati counted 2,076 first strokes in adults under 55: the rate rose from 34 to 62 per 100,000. In Oxford, young heart attacks fell over the same years.
- Body & Longevity
Lp(a): The Heart Risk Factor Science Still Can't Treat
Pelacarsen lowered Lp(a) in 8,323 HORIZON patients, but heart attacks and strokes did not fall. Why that gap between biomarker and outcome matters.
- AI at Work
GPT-6 Sol, Sonnet 5.5, Astra Shelved: September's Models, Tested
GPT-6 Sol got cheaper without getting smarter, Sonnet 5.5 got much smarter but not cheaper at full effort, and Astra 6.1 never shipped.
- Evidence Guides
Diet Soda Matched Water for Weight. The Word “Equivalent” Didn’t
In the SWITCH trial, diet drinkers lost 4.8 kg in two years and water drinkers 3.7 kg, but the way it proved sameness is the real lesson.
- Body & Longevity
Helping Others Slowed Cognitive Decline in People Carrying the Alzheimer's Risk Gene
A free behavior, a few hours a week, and a slower slope of decline for the gene that usually steepens it. The data are observational, and the paper says so.
- Body & Longevity
The First PCSK9 Pill Is Here. The Proof Still Comes From a Shot
A daily tablet now cuts LDL by more than half, while the injectable version of the same drug class was linked to 20% fewer deaths in people with no prior heart attack.
- Body & Longevity
Your Sleep Tracker Knows How Long You Slept. Not How Deeply
Every tracker in the lab studies could tell when people were asleep; none could reliably say how deeply, least of all in older adults and patients.
- Evidence Guides
How to Read a Health Study in 5 Minutes
Six checks: design, endpoint, absolute effect, population, status and funding, limits. The house method, in the open.
- Body & Longevity
Retatrutide Takes Weight Off. Viking Bets a Monthly Shot Keeps It
Retatrutide's 20.8% assumes nobody quit, and Viking's 90% comes from a group of 11. The numbers behind the two biggest obesity drug headlines of September.
- Body & Longevity
Deep Sleep and Alzheimer's: What Two New Studies Can and Can't Say
As tau builds in healthy older brains, deep sleep waves stop traveling and memory slips. A strong signal, but nobody yet knows which comes first.
- AI at Work
Rogue AI Agents in September: What Was Proven, What Was Claimed
Four AI agent security stories made September's headlines, and they rest on four very different grades of evidence.
- Body & Longevity
Diet and Exercise Moved 16 Aging Clocks. Supplements Didn’t
A Yale analysis of 51 studies finds diet and exercise move aging clocks reliably, if modestly, while over the counter supplements barely register.
- AI at Work
AI Eye Screening in Tanzania Nearly Doubled Specialist Follow Up in a Randomized Trial
The win was not a benchmark score. It was people with sight threatening eye disease actually reaching a specialist, and reaching one weeks sooner.
- AI at Work
AI Layoffs Lead the Headlines. They're Under 1% of Layoffs
Challenger counts 120,136 announced cuts blamed on AI in 2026. Federal data counts about 1.6 million layoffs every month. Both numbers are true.
- AI at Work
400 Scientists Want a Referee for Advanced AI
Hinton, Bengio and about 400 colleagues are asking for an international body to oversee the most capable AI systems. A public call, not yet a policy.
- Body & Longevity
Aprocitentan: Another Dial for Hard to Control Blood Pressure
Against placebo, the endothelin blocker lowered systolic pressure by about 4 mmHg on top of three drugs. New post hoc data on obesity and kidney risk.
- Body & Longevity
Biological Age Claims Need More Than One Clock
A Yale reanalysis of 12 epigenetic clocks says single clock drops don't reproduce. Then come the claims: GLP-1s, a skin cream, 2 to 3 years younger.
- Body & Longevity
CagriSema and EloraTZP Both Beat Tirzepatide. Read the Doses
Novo won at the low end of the dose range, 12.4 versus 9.1 percent. Lilly won at the top, 23.3 versus 14.8, and lost up to one patient in four to side effects.
- Body & Longevity
Myostatin Blockers Cut GLP-1 Muscle Loss. Strength Is Unproven
Trevogrumab and apitegromab saved kilograms of lean tissue in phase 2 trials, but no study has yet shown that it makes anyone stronger.
- Body & Longevity
The Lp(a) Test Everyone Should Get Once, and What It Can't Tell You
One blood test for life sounds simple, but this year's research shows the result can move, the risk has no clean cutoff, and no Lp(a) drug has proven it saves hearts.
- Body & Longevity
Muscle Without Meat After 55: What the IMPACT Trial Found
Twelve weeks of lifting: vegetarians gained 0.38 kg of limb muscle, omnivores 0.66 kg. The trial could not show the two diets were equivalent.
- AI at Work
Muse Wonder Full Lands Just Behind Opus 5.5
Meta's new flagship scores 56 on an independent index, two points behind Claude Opus 5.5. And the stronger model is not the one you can call today.
- Body & Longevity
A GLP-1 Pill Against Insulin: What ACHIEVE-4 Proved for the Heart
Orforglipron cleared a heart safety bar against insulin glargine, 4.2 versus 5.0 percent, and posted a mortality gap the trial was never built to prove.
- Body & Longevity
The Pill Duel: Orforglipron Beats Oral Semaglutide Head to Head
ACHIEVE-3, 1,698 adults, 52 weeks: in the primary analysis HbA1c fell 1.91 points against 1.47. A real head to head, run by one of the duelists.
- Body & Longevity
The Race to Keep Muscle on GLP-1s Reaches Phase 2
Sironax's FORGE-LM trial is half enrolled. The endpoint is body composition, which is the right question. Enrollment, though, is not a result.
- Body & Longevity
Your Body Clock Leaves a Signature on Your Wrist
809 adults, seven days of wrist sensors: robust temperature rhythms tracked with better metabolic markers, light with lower triglycerides. Association only.
Get Facts First, every Sunday
One email a week: the 5 facts that mattered in AI, health and longevity, each checked against the original source. No spam. Unsubscribe in one click.
By subscribing you agree to receive the newsletter. See the privacy policy.